Global News

CellCentric selects Sygnature Discovery for epigenetic prostate cancer program

Monday, September 9, 2013 12:01 PM

Sygnature Discovery, a provider of integrated drug discovery services, has been selected by CellCentric, a biotechnology company with a scientific foundation in epigenetics, to progress small molecule inhibitor drug discovery against a specific deubiquitinase (DUB) enzyme which has been demonstrated to play a key role in the progression of prostate cancer.

More... »

Oncodesign, Banook Central Imaging partner in pharmaco-imaging

Monday, September 9, 2013 12:00 PM

Oncodesign,a CRO  specializing in discovery of new anticancer therapies, and Banook Central Imaging, specializing in the centralized reading of medical images, have partnered to expand the use of new approaches in pharmaco-imaging.

More... »

MicroConstants China in-licenses liver cancer drug from Pertinax Therapeutics

Monday, September 9, 2013 11:54 AM

Site management organization and CRO MicroConstants China will in-license the China rights for a phase II liver cancer drug, PTX-9908, from Pertinax Therapeutics of Canada. MicroConstants China will be responsible for funding clinical development of PTX-9908 in China. Pertinax will receive a royalty in connection with sales, as well as any future assignment or transfer of the rights.

More... »

Arena Pharmaceuticals completes phase Ib clinical trial

Friday, September 6, 2013 03:12 PM

Arena Pharmaceuticals has completed a phase Ib clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The company plans to initiate a phase II clinical trial for APD811 in the first quarter of 2014.

More... »

Clintrak launches digital labeling service The DigiPly

Friday, September 6, 2013 03:03 PM

Clintrak, a clinical trial label company, has launched The DigiPly, a digital label service with benefits including enhanced turnaround times, quality control and flexible label options.

More... »

Otsuka to acquire Astex Pharmaceuticals

Friday, September 6, 2013 03:00 PM

Otsuka Pharmaceuticals will acquire Astex Pharmaceuticals for approximately $886 million, through a tender offer for all outstanding Astex shares expected to close in the fourth quarter.

More... »

Sanofi, Pozen ink exclusive license agreement

Friday, September 6, 2013 02:59 PM

Sanofi and Pozen, a pharmaceutical company specializing in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization, have announced an exclusive license agreement for commercialization of Pozen's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor (PPI), and enteric-coated (EC) aspirin in a single tablet (PA), PA8140 and PA32540. Sanofi will have exclusive rights to commercialize all PA combinations that contain 325mg or less of enteric-coated aspirin in the U.S. Pozen will receive an upfront payment of $15 million and will be eligible for pre-commercial milestone payments of up to $20 million and other future milestone payments and royalties on product sales. 

More... »

ThromboGenics acquires exclusive rights from Bicycle Therapeutics

Friday, September 6, 2013 02:57 PM

ThromboGenics, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema (DME).

More... »

The Clinical Trial Company opens new California office

Friday, September 6, 2013 02:56 PM

The Clinical Trial Company (TCTC), headquartered in the U.K., has incorporated a new U.S. business to meet the growing number of U.S. clients and sponsors, in the San Francisco Bay area.

More... »

Thermo Fisher Scientific, Siemens renew partnership

Friday, September 6, 2013 02:55 PM

Thermo Fisher and Siemens Healthcare Diagnostics have renewed their non-exclusive, long-term, royalty-bearing agreement for the use of Thermo Fisher’s Procalcitonin (B·R·A·H·M·S PCT) technology, currently available as an automated immunoassay on the Siemens ADVIA Centaur XP and CP systems in all countries outside the U.S. and China. The agreement extends a long-standing relationship between the companies.

More... »